BRUSH Sign: Radiolographic Marker of Cerebral Infarctus Prognosis

• Sponsor: Groupe Hospitalier Paris Saint Joseph (Other)
• Overall Status: Completed
• CT.gov ID: NCT03467269
• Collaborator: (none)
• Enrollment: 250
• Location: 1
• Actual Duration (Months): 4.1
• Patients Per Site Per Month: 60.4

Study Details

Study Description

Brief Summary

Today the treatment of ischemic stroke in acute phase is based on medicinal or endovascular revascularization. Cerebral MRI sequences help the diagnostic. This procedure uses deoxyhemoglobin as an endogenous tracer. This is also a scorer of cerebral ischemia and the increase lets visualized transcerebral veins in the suffering zone giving a brush aspect. Several studies show the interest of this sign and conclude that deoxyhemoglobin presence is a predictive factor of cerebral ischemia. The aim of the study is to evaluate this brush-sign and correlate it with the prognosis retrospectively.

Condition or Disease	Intervention/Treatment	Phase
Cerebral Infarction	Diagnostic Test: Brush sign

Study Design

• Study Type: Observational
• Actual Enrollment: 250 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: BRUSH Sign: Radiolographic Marker of Cerebral Infarctus Prognosis
• Actual Study Start Date: Feb 24, 2017
• Actual Primary Completion Date: Apr 1, 2017
• Actual Study Completion Date: Jun 30, 2017

Outcome Measures

Primary Outcome Measures

1. autonomy level [Month 3]

   measurement of autonomy level by mRS

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

• age>18 years old

• hospitalized for cerebral infarction

• MCA territory

• MRI within 24hours

• Sequence of magnetic susceptibility (SWAN)

Exclusion Criteria:

• Incomplete cerebral infarct

• MRI not possible

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Groupe Hospitalier Paris Saint Joseph	Paris	Ile-de-France	France	75014

Sponsors and Collaborators

• Groupe Hospitalier Paris Saint Joseph

Investigators

• Principal Investigator: ZUBER Mathieu, Professor, GHPSJ

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Groupe Hospitalier Paris Saint Joseph
• ClinicalTrials.gov Identifier: NCT03467269
• Other Study ID Numbers: BRUSH SIGN
• First Posted: Mar 15, 2018
• Last Update Posted: Mar 15, 2018
• Last Verified: Mar 1, 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Cerebral Infarction; Infarction

Study Results

No Results Posted as of Mar 15, 2018